Clinical trials
Lymphoblastic Lymphoma clinical trials
Below are recruiting lymphoblastic lymphoma clinical trials, each written for real people, not researchers. We’re tracking 157 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT01371630RecruitingPhase 1/Phase 2
Inotuzumab plus chemotherapy for certain types of childhood-like leukemia
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Houston, TexasAges 18 years+ - NCT06420076RecruitingPhase 1/Phase 2
Sequential CAR-T therapy for CD5/CD7 positive T-cell leukemia/lymphoma
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
Beijing, Beijing MunicipalityAges 2–90 - NCT05681260RecruitingPhase 3
Methotrexate dose comparison for newly diagnosed T-cell lymphoma
This Phase 3 trial compares a higher dose of methotrexate versus an escalating (step-up) methotrexate plan in children newly diagnosed with T-cell lymphoblastic lymphoma. The goal is to see which dosing approach works better and is safe enough to use as standard treatment.
Shanghai, Shanghai MunicipalityAges 1–18 - NCT03810196Recruiting
Stem cell addback after transplant to treat viral or fungal infection
This study tests a stem cell “addback” treatment after a specific type of transplant (with certain immune cells removed). It may help the body recover faster and fight serious viral or fungal infections in children and teens.
Philadelphia, PennsylvaniaAges Up to 25 years - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT06289673RecruitingPhase 4
Collecting info to start treatment for new leukemia or lymphoma
This study gathers key health information at the start of treatment for children and teens newly diagnosed with certain types of leukemia or lymphoma. The goal is to find the best way to begin therapy right away, without waiting for extra tests.
San Diego, CaliforniaAges 1–18 - NCT07020533RecruitingPhase 1
CMV vaccine for stem cell transplant recipients
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT06355739Recruiting
CAR T cells for children with relapsed B-cell leukemia
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
Tianjin, Tianjin MunicipalityAges 3–18 - NCT03081910RecruitingPhase 1
CAR T cells made from your own cells to treat CD5 tumors
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Houston, TexasAges Up to 75 years - NCT07220993RecruitingPhase 1
Modified immune cells for aggressive T-cell cancers
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
Houston, TexasAges Up to 75 years - NCT07499128Enrolling by invitation
Continuous temperature monitoring for cytokine release syndrome
This study tests a wearable device that continuously monitors your body temperature to detect cytokine release syndrome, a possible side effect of certain immunotherapies. The goal is to catch it early so you can get treatment faster.
Bethesda, MarylandAges 18–120 - NCT04972942RecruitingPhase 1
Immunotherapy for high-risk T-cell blood cancers after transplant
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Phoeniz, ArizonaAges Up to 39 years - NCT02877303RecruitingPhase 2
Frontline drug treatment for newly diagnosed B-cell leukemia
This trial tests a combination of targeted and chemotherapy medicines as first treatment for newly diagnosed B-cell acute lymphoblastic leukemia (ALL) or related lymphoblastic lymphoma. It aims to improve how well treatment controls the leukemia and how long people can stay in remission.
Houston, TexasAges 14 years+ - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Birmingham, AlabamaAges Any age - NCT06101381RecruitingPhase 1/Phase 2
Car-T cell therapy for relapsed or refractory leukemia and lymphoma
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
Campinas, São PauloAges 3–70 - NCT06633341RecruitingEarly Phase 1
CAR-T cell therapy for CD5+ T-cell lymphoma
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
Hangzhou, ZhejiangAges Any age - NCT03932903Recruiting
Phone coaching to help teens stay on leukemia medicine
This trial tests a mobile (phone) health program to help adolescents and young adults with leukemia take their oral chemotherapy medicine consistently. It may help if staying on daily pills is hard during the maintenance phase of treatment.
Chicago, IllinoisAges 14 years+ - NCT07632014Recruiting
Cancer Care Study for Young People Ages 0–21
This research study follows young people (babies through age 21) who have been diagnosed with cancer and are currently receiving treatment or in follow-up care. The study aims to better understand their care experiences and outcomes.
YerevanAges birth–21 years - NCT06710418Recruiting
Comparing two red blood cell transfusion thresholds for people with high-grade myeloid neoplasms, AML or B-ALL
This study compares two different strategies for when to give red blood cell transfusions to people receiving intensive chemotherapy or stem cell transplant for high-grade myeloid neoplasms, AML or B-ALL. The goal is to see which approach better improves quality of life and daily function.
Seattle, WashingtonAges 18 years+ - NCT07071051Recruiting
Study of calaspargase pegol on blood clotting in pediatric leukemia
This study looks at how a chemotherapy drug called calaspargase pegol affects blood clotting in children and young adults with leukemia. It will help doctors understand if changes in clotting are common and safe.
Rochester, MinnesotaAges 2–22
Hear when a new Lymphoblastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoblastic lymphoma?
- Yes. Clin2 currently lists 157 recruiting lymphoblastic lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoblastic lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoblastic lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.